This retrospective study describes outcome in patients with CML after allografting using dose-reduced conditioning with fludarabine (125-180 mg/sqm) and busulphan (8 mg/kg). 44 Ph+ve patients were transplanted in 9 German centres; 26 patients in chronic phase, 11 in accelerated phase and 7 in blast crisis. Gratwohl scores for these patients were: 1 (n=2), 2 (n=2), 3 (n=10), 4 (n=18), 5 (n=9) and 6 (n=3). 23 patients had received prior interferon-alpha therapy. Grafts from unrelated donors were HLAmatched in 15 cases and mismatched in 8 cases, while grafts from related donors were HLA-matched in 19 cases, and mismatched in 2 cases. GVHD prophylaxis was cyclosporine (CSA) in 20 cases, CSA + mycophenolate mofetil (MMF) in 13 cases, CSA and methotrexate in 9 cases, CSA and steroids in 1 case, and MMF alone in 1 case. A total of 34 patients achieved a complete remission and 18 are alive and disease-free at a median follow-up of 230 days (range 9-619). The incidence of acute GVHD (Grade II-IV) was 43%. 16 patients have died, 14 of causes unrelated to relapse. Risk factors predisposing to graft failure were: an unrelated donor vs a related donor (8/23 vs 2/21, p=0.07), and interferon therapy within 90 days of transplant (4/6 vs 3/17, p=0.025). Of 31 patients for whom molecular or cytogenetic data were available, 16 patients (52%) were PCR-ve, and 7 patients (23%) were Ph-ve by fluorescent in situ hybridisation, at last follow-up. These findings demonstrate durable engraftment and a low rate of relapse after fludarabine-containing reduced conditioning, but highlight the need for effective GvHD and rejection prophylaxis in this population, many of whom were not eligible for high-dose conditioning due to age, reduced performance status, prior complications, or extensive pre-treatment. They also support the discontinuation of interferon therapy at least 90 days before transplant to avoid possible adverse effects on engraftment.
A.M. Carella, M.T. Corsetti, M. Cavaliere, E. Lerma (Genoa, I) In the past eleven years we have autografted 91 patients in chronic phase CML. The median age was 45 years (range, 20-65) . These patients were in late chronic phase and refractory to interferon-alpha (IFN-alpha) (n= 48) (Group A) or in early chronic phase not previously treated with IFN-alpha (n=43) (Group B). All patients were treated with ICE/mini-ICE protocols plus G-CSF to mobilize hematopoietic stem cells. High dose therapy consisted of TBI-conditioning regimen (n=18) or high-dose Busulfan (4 mg/kg/d for 4 days) (n=73). After engraftment, all patients received immunological therapy with IFN-alpha or IFN-alpha/IL-2, in an attempt to delay blast crisis. Sixty-eight (74%) patients are alive 2 to 99 months (median, 35 months) after autografting. Statistical analysis with Logrank (Mantel-Cox) test showed a significant difference in terms of survival after autografting in favor of Group B (P value 0.0079) Twenty-one patients (Group A: 17; Group B: 4) went on to develop fatal blast crisis. Twenty-eight (41%) patients (Group B: 19; Group A: 9) are in complete/major cytogenetic remission at a median of 37 months (range, 9-99). One patient in Group B with HBV+ died of fulminant hepatitis 4 months after autografting; two other patients in Group A died of infections during aplasia. All patients had some degree of stomatitis, which was more severe in Group A patients. Gastrointestinal and hepatic toxicities were observed mainly in patients in Group A. Most autograft recipients in Group B reported normal or near normal activity and energy levels. We conclude that autografting with Ph-negative or * 35% Ph-positive mobilized hematopoietic progenitor cells can result in prolonged restoration of Ph-negative hematopoiesis for some patients with CML. In addition, when employed during the early phase of disease, this procedure need not be associated with either prolonged convalescence or with chronic debility.
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Early autologous stem cell transplantation for poor-risk Chronic Lymphocytic Leukemia (CLL): prognostic factors for feasibility and molecular outcome P. Dreger, N. von Neuhoff, G. Wittkowsky, R. Sonnen, B. Seyfarth, R. Kuse, B. Glass, N. Schmitz (Kiel, Hamburg, D) The aim of this prospective study was to investigate whether autologous stem cell transplantation (SCT) might be a curative treat-ment for poor-risk CLL if administered early during the course of the disease. 77 patients with symptomatic (n=51) or asymptomatic CLL and adverse prognostic factors (high lymphocyte count, short lymphocyte doubling time, or 11q-deletion; n=26) underwent a sequential treatment strategy comprising initial cytoreduction with CHOP or fludarabine, intensive chemotherapy for mobilization of peripheral blood stem cells (PBSC), and high-dose radiochemotherapy followed by autotransplantation of immuno-magnetically purged stem cells. Results: 61 patients (79%) had a suitable graft available and were in a state of minimal disease after mobilization. 16 patients not matching these criteria were regarded as pretransplant failures. Significant risk factors for pretransplant failure by univariate analysis were Ͼ1 line of pretreatment (failure probability 46%; p=0.0006), symptomatic disease, Binet stage, and high lymphocyte count, whereas sex, age, and time from diagnosis had no influence. SCT was performed in 63 patients. Toxicity was acceptable with two treatment-related deaths. Three-year probabilities were 0.94 for overall survival (OS), 0.82 for event-free survival (EFS), 0.15 for clinical progression, and 0.33 for molecular clonality by consensus primer CDR3 PCR. Clone-specific primers for sensitive Taqman CDR3 amplification were available for 30 patients and revealed persistence of the leukemic clone in 24 of them (80%). High lymphocyte count was the only independent vari-able predicting for molecular relapse while symptomatic stage did not affect any post transplant endpoint. However, when all 77 patients were analyzed by intention to treat, the probabilities of OS and EFS at 3 years were 0.87 and 0.64, respectively, with a significant benefit for asymptomatic patients (3-year EFS 0.79 vs. 0.57, p=0.034). Follow-up was 21 (1-82) months. Conclusions: SCT does not appear to be a curative treatment for poor-risk CLL, even if performed early during the course of the disease. Nevertheless, survival data are promising and suggest a particularly good outcome for early patients due to a better feasibility of the procedure. The prognosis of patients with chronic lymphocytic leukemia (CLL) relapsing after fludarabine or autologous stem cell transplantation (SCT) is poor. Allogeneic SCT might be an option in this situation since CLL is known to be strongly sensitive to graft-versus-leukemia (GVL) effects. However, allografting for CLL using conventional conditioning has been hampered by an extremely high treatment-related mortality. In order to avoid toxicity but take advantage of GVL activity, we have studied allotransplantation in CLL using an intensity-reduced conditioning regimen consisting of a combination of fludarabine (F) and cyclophosphamide (C). Seven patients with symptomatic CLL and high-risk features were eligible. Median age was 53 (43-57) years. Previous therapy consisted of 3 (2-5) regimens; autologous stem cell mobilization had failed in 4 patients. Four patients were in partial remission and three patients had progressive disease at time of transplant. Conditioning regimen consisted of daily F 30mg/m 2 and C 500mg/m 2 over 5 days; GVHD prophylaxis was performed with CSA/short-course MTX or CSA/MMF. PBSC were obtained from HLA-identical donors (6 siblings and one unrelated donor). Results: Hematopoietic recovery occurred in all patients with a median time to neutrophil recovery of 16 (7-26) days and a median number of 2 (0-18) transfused platelet units. As assessed by XY-FISH or STR-PCR, complete or predominant hematopoietic donor chimerism was achieved over time although initial recovery of hematopoiesis was at least partially autologous in most cases. Early non-hematological toxicity was very low. Five patients experienced acute and/or chronic GVHD; in two cases chronic GVHD was associated with immunologic and molecular clearance of residual disease surviving conditioning chemotherapy. With 4 (2-16) months of follow-up, all patients are alive and progression-free. Conclusions: In spite of its low early toxicity, allo-SCT with FC conditioning in patients with poorrisk CLL allows establishment of complete lymphohematopoietic donor chimerism, thereby providing significant GVL effects. In terms of GVHD, however, this dose-reduced regimen seems not to be different from conventional conditioning. The conditioning was with BuCy, (n=44), cyclo/TBI (n=79), melphalan/TBI (n=6), mel/cyclo/TBI (n=11). GVHD prophylaxis was CyA alone (n=68), CyA+Mtx (n=69) or other (n=4). The overall survival for 141 patients was 40% at 5 years. There was no difference in 5yr. survival for either sex group (44% in males and 33% in females, p=0.45). Survival was significantly better in patients who received CyA+Mtx for GVHD prophylaxis as compared to others (50% vs. 25% at 5 yr.; p=0.003). Similarly, survival was significantly better for patients who were conditioned with non-TBI regimen as compared to TBI conditioned patients (57% vs. 32% at 5 yr.; p=0.027). The number of patients receiving unrelated transplant was small, but there were no differences in survival between patient receiving sibling and unrelated transplants. The patients who received BuCy conditioning and CyA+Mtx as GVHD prophylaxis had significantly better survival as compared to those who received TBI or CyA alone(69% vs. 28% at 5 yr.; p=0.0007). In multivariate analysis, use of CyA+Mtx (RR:2.0 95%CI: 1.1-3.9, p=0.001),sibling donor (RR:2.3, 95%CI:1.25-4.2,p=0.008) and transplant within 1yr of diagnosis (RR:1.7, 95%CI:1.04-2.6, p=0.04) were associated better chances of survival. Transplant related mortality was significantly higher in patients receiving CyA alone as compared to those who received CyA+Mtx (32% vs. 71% at 1 year; pϽ0.0001). One-year transplant related mortality was 28% for patients receiving BuCy/CyA+Mtx as compared to others (p=0.0016). 5 yr. probability of relapse was 22% and there was a trend toward lower relapse rate in male patients and those who received sibling transplant. This single centre analysis shows that use of busulfan and cyclophosphamide with Cyclosporine/methotrexate as GVHD prophylaxis is gives best results of allogeneic transplant in CML, especially in HLA matched sibling donor-patient pairs. The benefit is likely to be due to reduced transplant related mortality. Background: Even with allogeneic stem cell transplantation (SCT), long-term survival of CML patients transplanted in blast crisis (BC) hardly exceeds 5% and SCT in 2nd chronic phase (CP) after intensive chemotherapy (CT) is preferable. However, CT is associated with significant toxicity, and response rates in myeloid BC are low. In contrast, STI571 induces remissions in most patients with minimal toxicity. Thus, we explored the combination of STI571 with subsequent allogeneic SCT. Patients: Four patients in myeloid BC (previously untreated for BC) and 2 in partial remission after ALL-type CT for lymphoid BC were treated with STI571 (mean duration of treatment 103 days). Four patients achieved a 2nd CP and 2 a reduction of bone marrow blasts. Four patients underwent allografting immediately after stopping STI571 (3 in CP, 1 in partial remission from myeloid BC). Two patients had relapsed while on STI571 but had responded to conventional salvage therapy prior to SCT. Transplants: Three patients were transplanted from unrelated matched, 2 from unrelated 1-antigen-mismatched and 1 from a
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Results of allogeneic transplant in patients with
